Trial for gout drug meets primary endpoint, raises safety

March 12th, 2018 | Posted by admin in Uncategorized

Febuxostat, a gout drug that has been in use for nearly a decade, was found to significantly increase the risk of death, even though it did not raise the risk of the trial's primary endpoint, a combined rate of fatal and nonfatal adverse cardiovascular events, according to new research.
Source: Health Medicine Science Daily

You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *